奥希替尼联合贝伐珠单抗治疗EGFR T790M突变晚期肺腺癌的临床观察  

Clinical observation of osimertinib combined with bevacizumab in the treatment of patients with advanced lung adenocarcinoma and EGFR T790M mutation

作　　者：王雨婷 陈凯 WANG Yu-ting;CHEN Kai(Department of Oncology,Tianjin Fourth Central Hospital,Tianjin 300140,China)

机构地区：[1]天津市第四中心医院肿瘤科,天津300140

出　　处：《中国处方药》2024年第8期8-11,共4页Journal of China Prescription Drug

摘　　要：目的探讨表皮生长因子受体(EGFR)T790M突变晚期肺腺癌患者应用奥希替尼(AZD9291)、贝伐珠单抗联合治疗的临床疗效。方法选取2020年1月~2023年6月接受治疗的经病理及基因检测证实EGFR T790M突变晚期肺腺癌患者96例进行研究。使用动态随机法将上述患者分为对照组(n=48)与观察组(n=48)。对照组给予奥希替尼治疗,观察组给予贝伐珠单抗联合奥希替尼治疗。比较两组近期疗效、远期疗效、血清指标[糖类抗原125(CA125)、癌胚抗原(CEA)、血管内皮生长因子(VEGF)]以及不良反应。结果观察组的近期疗效显著优于对照组(P<0.05);观察组进展率与病死率均低于对照组(P<0.05);观察组无进展生存期长于对照组(P<0.05);治疗后观察组CA125、CEA、VEGF均低于对照组(P<0.05);观察组的贫血、高血压、蛋白尿、皮疹发生率与对照组比较,差异无统计学意义(P>0.05)。结论对于EGFR T790M突变晚期肺腺癌患者,使用贝伐珠单抗联合奥希替尼治疗可提高近、远期疗效,降低肿瘤标志物表达水平,且不会增加不良反应的发生率。Objective To explore the clinical observation of osimertinib(AZD9291)combined with bevacizumab in the treatment of patients with advanced lung adenocarcinoma and epidermal growth factor receptor(EGFR)T790M mutation.Methods A total of 96 patients with advanced lung adenocarcinoma and EGFR T790M mutation who were confirmed by pathological examination and gene detection in the hospital were enrolled between January 2020 and June 2023.According to dynamic randomization method,they were divided into the control group(n=48,osimertinib)and the observation group(n=48,bevacizumab combined with osimertinib).The short-term and long-term curative effect,serum indexes[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)]and adverse reactions were compared between the two groups.Results The short-term curative effect in the observation group was significantly better than that in the control group(P<0.05).The progression rate and mortality in the observation group were all lower than those in the control group(P<0.05),and progression-free survival was longer than that in the control group(P<0.05).After treatment,levels of CA125,CEA and VEGF in the observation group were lower than those in the control group(P<0.05).There was no significant difference in incidence of anemia,hypertension,proteinuria and rash between the two groups(P<0.05).Conclusion Bevacizumab combined with osimertinib can improve short-term and long-term curative effect,and reduce levels of tumor markers in patients with advanced NSCLC and EGFR T790M mutation,which will not increase the risk of adverse reactions.

关 键 词：表皮生长因子受体 奥希替尼 肺腺癌 贝伐珠单抗 

分 类 号：R734.2[医药卫生—肿瘤]